ArticleLiver international : official journal of the International Association for the Study of the Liver2023
Impact on follow-up strategies in patients with primary sclerosing cholangitis.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Pharmacokinetic modelling of MRI-based liver function for risk assessment in primary sclerosing cholangitis: a prospective pilot study.European radiology experimental · 2026Article
- Annual magnetic resonance cholangiopancreatography surveillance outcomes in individuals with primary sclerosing cholangitis.Internal medicine journal · 2026Article
- Evaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation.JHEP reports : innovation in hepatology · 2026Review
- Endoscopic retrograde cholangiopancreatography and primary sclerosing cholangitis: a retrospective study of a high-volume program.Journal of the Canadian Association of Gastroenterology · 2025Article
- A retrospective evaluation of preemptive liver transplantation for bile duct dysplasia in primary sclerosing cholangitis: Balancing risks and benefits.JHEP reports : innovation in hepatology · 2025Article
- MR imaging and cholangiography show suboptimal performance for diagnosing ductal cholangiocarcinoma in primary sclerosing cholangitis patients.European radiology · 2025Article
- Non-Adherence to Standard Therapy in Autoimmune Hepatitis: Impact of Steroid Use and Over-the-Counter Medications.United European gastroenterology journal · 2025Article
- Primary sclerosing cholangitis.Nature reviews. Disease primers · 2025Review
- Surrogate markers of bile duct disease progression in primary sclerosing cholangitis - A prospective study with repeated ERCP examinations.JHEP reports : innovation in hepatology · 2024Article
- Clinical outcomes and reintervention after endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis in absence of cholangitis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Long-term impact of scheduled regular endoscopic interventions for patients with primary sclerosing cholangitis.Hepatology communications · 2024Article
- Review
- Quantitative Magnetic Resonance Cholangiopancreatography Scoring and Its Predictive Value for Outcomes in Adults with Primary Sclerosing Cholangitis.Journal of clinical medicine · 2024Article
- Dominant stricture in paediatric-onset primary sclerosing cholangitis is associated with impaired prognosis in a long-term follow-up.United European gastroenterology journal · 2024Article
- Surveillance MRI is associated with improved survival in patients with primary sclerosing cholangitis.Hepatology communications · 2024Article
- Update on the optimisation of endoscopic retrograde cholangiography (ERC) in patients with primary sclerosing cholangitis.Frontline gastroenterology · 2024Article
- Current Therapeutics in Primary Sclerosing Cholangitis.Journal of clinical and translational hepatology · 2023Review
- Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies.Cancers · 2023Review
- Impact on follow-up strategies in patients with primary sclerosing cholangitis.Liver international : official journal of the International Association for the Study of the Liver · 2023Article
- Forty-five-year trends in intra- and extrahepatic cholangiocarcinoma: sex- and race-based insights.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 20 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsEvidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies in PSC with the hypothesis that regular imaging improves survival.
methodsWe collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality.
resultsA broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow-up, was 0.61 (0.47-0.80) for scheduled imaging with and without ERCP; 0.64 (0.48-0.86) for US/MRI and 0.53 (0.37-0.75) for follow-up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high-grade dysplasia as a time-dependent covariate, HR 0.57 (0.44-0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow-up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed.
conclusionsFollow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.